LIVIVO - Search results -

Search results

Result 1 - 10 of total 122

Search options

Article ; Online: Human papillomavirus-related malignancies in HIV infection: anal and oropharyngeal cancers.

Wilkin, Timothy J

2018 Volume 26, Issue 3, Page(s) 85–88

Abstract: ... summarizes a presentation by Timothy J. Wilkin, MD, MPH, at the IAS-USA continuing education program held ...

Abstract	Human papillomavirus (HPV)-related cancers, including anal cancer and oropharyngeal cancer, occur more frequently in individuals living with HIV infection than in the general population. Strategies for prevention among individuals with HIV infection include HPV vaccination, anal cancer screening programs, and early initiation of antiretroviral therapy (ART). HPV vaccination is not yet optimally used; a stronger and more persistent effort is needed to increase vaccination rates. Although anal cancer screening is not recommended by all authorities, there is a least some evidence that screening and treatment of anal high-grade squamous intraepithelial lesions may prevent progression to cancer. However, more definitive evidence is needed. Early initiation of ART reduces the risk of infection-related cancers, with some evidence of benefit in preventing HPV-associated cancer in individuals with HIV infection. This article summarizes a presentation by Timothy J. Wilkin, MD, MPH, at the IAS-USA continuing education program held in Los Angeles, California in April 2018.
MeSH term(s)	Anti-Retroviral Agents/therapeutic use ; Anus Neoplasms/epidemiology ; Anus Neoplasms/pathology ; Anus Neoplasms/prevention & control ; Early Detection of Cancer ; Female ; HIV Infections/complications ; HIV Infections/drug therapy ; Humans ; Oropharyngeal Neoplasms/epidemiology ; Oropharyngeal Neoplasms/pathology ; Oropharyngeal Neoplasms/prevention & control ; Papillomavirus Infections/complications ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/prevention & control ; Papillomavirus Vaccines/administration & dosage ; Squamous Intraepithelial Lesions of the Cervix/diagnosis ; Squamous Intraepithelial Lesions of the Cervix/epidemiology ; Squamous Intraepithelial Lesions of the Cervix/pathology ; Squamous Intraepithelial Lesions of the Cervix/therapy
Chemical Substances	Anti-Retroviral Agents ; Papillomavirus Vaccines
Language	English
Publishing date	2018-10-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2656632-1
ISSN	2161-5853 ; 2161-5861
ISSN (online)	2161-5853
ISSN	2161-5861
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Tecovirimat for Mpox-Promise and Limitations.

Zucker, Jason / Fischer, William A / Wilkin, Timothy

JAMA internal medicine

2024 Volume 184, Issue 3, Page(s) 279–280

MeSH term(s)	Humans ; Mpox (monkeypox) ; Benzamides
Chemical Substances	Benzamides
Language	English
Publishing date	2024-01-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	2699338-7
ISSN	2168-6114 ; 2168-6106
ISSN (online)	2168-6114
ISSN	2168-6106
DOI	10.1001/jamainternmed.2023.7693
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.119: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CROI 2023: Advances in Antiviral Therapy in HIV and Viral Hepatitis.

Gunaratne, Shauna H / Taylor, Barbara S / Wilkin, Timothy J / Tieu, Hong-Van

Topics in antiviral medicine

2023 Volume 31, Issue 3, Page(s) 445–467

Abstract: Several innovative methods were presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI) targeting different aspects of the HIV care continuum to improve testing, linkage to care, and viral suppression. Some of these ... ...

Abstract	Several innovative methods were presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI) targeting different aspects of the HIV care continuum to improve testing, linkage to care, and viral suppression. Some of these approaches were directed at more vulnerable groups, such as pregnant women, adolescents, and individuals who inject drugs. In contrast was the devastating impact of the COVID-19 pandemic, with negative outcomes on HIV viral load suppression and retention in care. Data were presented on hepatitis B virus (HBV) suppression showing that tenofovir alafenamide (TAF)/emtricitabine (FTC)/bictegravir (BIC) may be superior to tenofovir disoproxil fumarate/FTC plus dolutegravir in suppressing HBV in HIV/HBV-coinfected individuals. A pilot study examining a 4-week trial of direct-acting antiviral therapy to treat hepatitis C in recently infected individuals showed lower rates of sustained virologic response at 12 weeks than longer courses. Additional data were presented on the use of long-acting cabotegravir/rilpivirine, comparing this regimen with oral TAF/FTC/BIC and the use of long-acting cabotegravir/rilpivirine in those with viremia. Data were presented on a novel strategy of lenacapavir with 2 broadly neutralizing antibodies given every 6 months as maintenance antiretroviral therapy (ART). Data were presented on improving HIV care outcomes in adolescents, interventions to prevent mother-to-child transmission, and HIV reservoirs in children and adolescents. Data were also presented on interactions between ART and hormonal contraception, as well as ART-related weight gain and impact on pregnancy. A study examining BIC pharmacokinetics in pregnancy was presented, as well as retrospective data on outcomes of adolescents receiving TAF/FTC/BIC.
MeSH term(s)	Adolescent ; Female ; Humans ; Pregnancy ; Anti-HIV Agents/therapeutic use ; Anti-Retroviral Agents/therapeutic use ; COVID-19 ; Emtricitabine/therapeutic use ; Hepatitis C, Chronic ; Infectious Disease Transmission, Vertical ; Pandemics ; Pilot Projects ; Retrospective Studies ; Retroviridae Infections ; Rilpivirine
Chemical Substances	Anti-HIV Agents ; Anti-Retroviral Agents ; bictegravir (8GB79LOJ07) ; Emtricitabine (G70B4ETF4S) ; Rilpivirine (FI96A8X663)
Language	English
Publishing date	2023-06-12
Publishing country	United States
Document type	Clinical Trial ; Journal Article
ZDB-ID	2656632-1
ISSN	2161-5853 ; 2161-5853
ISSN (online)	2161-5853
ISSN	2161-5853
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States.

Meites, Elissa / Wilkin, Timothy J / Markowitz, Lauri E

Human vaccines & immunotherapeutics

2022 Volume 18, Issue 1, Page(s) 2016007

Abstract: Gay, bisexual, and other men who have sex with men (MSM) and transgender women, particularly those who are living with HIV, are disproportionately affected by human papillomavirus (HPV). For this narrative review of HPV health outcomes and vaccination ... ...

Abstract	Gay, bisexual, and other men who have sex with men (MSM) and transgender women, particularly those who are living with HIV, are disproportionately affected by human papillomavirus (HPV). For this narrative review of HPV health outcomes and vaccination for gay, bisexual, and other MSM and transgender women in the United States, we highlighted 71 publications regarding 1) burden of HPV infections and related diseases; 2) HPV vaccine efficacy; 3) HPV vaccination recommendations; 4) HPV vaccination coverage; 5) real-world vaccine effectiveness and health impacts; and 6) HPV vaccination acceptability. Vaccination is effective at reducing HPV infections among MSM; in the United States, routine HPV vaccination is recommended for all adolescents at age 11-12 years and for all persons through age 26 years. Efforts are ongoing to increase vaccination coverage and monitor health impacts of vaccination. Increasing vaccination coverage before sexual exposure to HPV is expected to reduce the burden of HPV-related disease.
MeSH term(s)	Adolescent ; Adult ; Alphapapillomavirus ; Child ; Female ; Homosexuality, Male ; Humans ; Male ; Papillomaviridae ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/prevention & control ; Papillomavirus Vaccines ; Sexual and Gender Minorities ; Transgender Persons ; United States ; Vaccination
Chemical Substances	Papillomavirus Vaccines
Language	English
Publishing date	2022-03-16
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2664176-8
ISSN	2164-554X ; 2164-5515
ISSN (online)	2164-554X
ISSN	2164-5515
DOI	10.1080/21645515.2021.2016007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6967: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidates.

Sugarman, Jeremy / Weir, Brian W / Dun, Chen / Gulick, Roy M / Wilkin, Timothy J / Mayer, Kenneth H / McCauley, Marybeth / Weinfurt, Kevin P

AIDS care

2024 , Page(s) 1–7

Abstract: When participants enrolled in an HIV prevention trial hold a preventive misconception (PM) - expectations that experimental interventions will confer protection from HIV infection - they may engage in behaviors that increase their risk of acquiring HIV. ... ...

Abstract	When participants enrolled in an HIV prevention trial hold a preventive misconception (PM) - expectations that experimental interventions will confer protection from HIV infection - they may engage in behaviors that increase their risk of acquiring HIV. This can raise ethical concerns about whether those enrolled in the trial understand the nature of participation and their safety. Consequently, we systematically evaluated the prevalence of PM and its association with risk behaviors in a trial examining three candidate regimens for oral HIV pre-exposure prophylaxis in which all participants received at least one antiretroviral agent. Overall, trial participants exhibited relatively high preventive expectations that may be associated with an increase in risk behaviors among men who have sex with men. In addition, we identified substantial site variability in PM that necessitates future research to uncover its source. This will allow appropriate measures to be taken to mitigate PM and help ensure that participants have an accurate understanding of the potential risks and benefits of trial participation throughout the course of a trial.
Language	English
Publishing date	2024-04-12
Publishing country	England
Document type	Journal Article
ZDB-ID	1012651-x
ISSN	1360-0451 ; 0954-0121
ISSN (online)	1360-0451
ISSN	0954-0121
DOI	10.1080/09540121.2024.2332446
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2799: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Another Call for Widespread Human Papillomavirus Vaccination.

Ellsworth, Grant B / Wilkin, Timothy J

The Journal of infectious diseases

2019 Volume 222, Issue 2, Page(s) 171–172

MeSH term(s)	Alphapapillomavirus ; HIV ; Humans ; Incidence ; Male ; Papillomavirus Infections/prevention & control ; Papillomavirus Vaccines ; Prevalence ; Vaccination
Chemical Substances	Papillomavirus Vaccines
Language	English
Publishing date	2019-09-23
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
ZDB-ID	3019-3
ISSN	1537-6613 ; 0022-1899
ISSN (online)	1537-6613
ISSN	0022-1899
DOI	10.1093/infdis/jiz426
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.50: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 445: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Benefits and limitations of different study designs for long-acting antiretroviral therapy among people living with HIV with viremia.

Gandhi, Monica / Nachega, Jean / Miller, Veronica / Wilkin, Timothy

Journal of the International AIDS Society

2023 Volume 26 Suppl 2, Page(s) e26093

MeSH term(s)	Humans ; Viremia/drug therapy ; HIV Infections/drug therapy
Language	English
Publishing date	2023-07-12
Publishing country	Switzerland
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2467110-1
ISSN	1758-2652 ; 1758-2652
ISSN (online)	1758-2652
ISSN	1758-2652
DOI	10.1002/jia2.26093
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: CROI 2022: advances in antiviral therapy for HIV, COVID-19, and viral hepatitis.

Gunaratne, Shauna H / Tieu, Hong-Van / Wilkin, Timothy J / Taylor, Barbara S

Topics in antiviral medicine

2022 Volume 30, Issue 3, Page(s) 490–521

Abstract: The 2022 Conference on Retroviruses and Opportunistic Infections provided a rich source of new data and comprehensive reviews on antiviral therapy. For COVID-19, intramuscular sotrovimab was noninferior to intravenous sotrovimab, serostatus did not ... ...

Abstract	The 2022 Conference on Retroviruses and Opportunistic Infections provided a rich source of new data and comprehensive reviews on antiviral therapy. For COVID-19, intramuscular sotrovimab was noninferior to intravenous sotrovimab, serostatus did not predict the efficacy of sotrovimab, and molnupiravir appeared safe and modestly effective in decreasing hospitalization rates. Trials from low- and middle-income countries provided data to support transitioning those on first-line therapy with or without virologic suppression and those virologically suppressed on second-line therapy to dolutegravir-based regimens. Additional data supported the use of lenacapavir as a long-acting antiretroviral drug. Data across the United States demonstrate the negative impact of the COVID-19 pandemic on the HIV care continuum, although enhanced outreach efforts and decentralization of antiretroviral therapy delivery were associated with improvements in care engagement outcomes. Researchers described potential mechanisms for the emergence of integrase strand transfer inhibitor resistance. Studies on proviral genotyping high-lighted the limitations of its use in predicting clinically significant resistance. Several studies looked at the epidemiology and treatment of hepatitis C and B and the status of current hepatitis C virus elimination efforts. Data presented on HIV, COVID-19, and maternal and pediatric health included 2-year virologic outcome data of very early antiretroviral therapy in potentially reducing the latent HIV reservoir in infants with HIV. Data presented on COVID-19 and HIV therapeutics in children included SARS-CoV-2-neutralizing monoclonal antibodies in children younger than 12 years of age, remdesivir in hospitalized infants and children, and long-acting therapies for HIV treatment in children.
MeSH term(s)	Child ; Humans ; United States/epidemiology ; HIV Infections/drug therapy ; COVID-19/drug therapy ; Pandemics ; HIV-1 ; SARS-CoV-2 ; Virus Latency ; Anti-Retroviral Agents/therapeutic use ; Hepatitis, Viral, Human
Chemical Substances	sotrovimab (1MTK0BPN8V) ; Anti-Retroviral Agents
Language	English
Publishing date	2022-11-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	2656632-1
ISSN	2161-5853 ; 2161-5853
ISSN (online)	2161-5853
ISSN	2161-5853
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: CROI 2021: Advances in Antiretroviral Therapy for HIV and Antiviral Therapy for COVID-19.

Gunaratne, Shauna H / Tieu, Hong-Van / Wilkin, Timothy J / Taylor, Barbara S

Topics in antiviral medicine

2021 Volume 29, Issue 3, Page(s) 361–378

Abstract: The 2021 Conference on Retroviruses and Opportunistic Infections included advances in therapy for HIV as well as for SARS-CoV-2. Data presented on COVID-19 therapies included trials showcasing the use of monoclonal antibodies for prevention and treatment ...

Abstract	The 2021 Conference on Retroviruses and Opportunistic Infections included advances in therapy for HIV as well as for SARS-CoV-2. Data presented on COVID-19 therapies included trials showcasing the use of monoclonal antibodies for prevention and treatment of COVID-19. Promising new data were presented on lenacapavir, an investigational HIV capsid inhibitor given as a subcutaneous injection every 6 months. Although encouraging data from settings across the globe reported achievement of 90-90-90 HIV care cascade targets, disparities exist in care engagement and viral suppression, particularly for people of color and young people with HIV. Several interventions were associated with improved care cascade outcomes. The COVID-19 pandemic has impacted HIV care engagement, but mitigation strategies can allow programs to continue to serve people with HIV during the pandemic. Studies examining the resistance patterns of existing antiretroviral therapy (ART) agents were presented, as were resistance mechanisms of novel agents such as lenacapavir and resistance patterns among individuals who seroconverted while on preexposure prophylaxis. Data from large observational cohorts were presented on patterns of ART uptake and trends in mortality and in virologic failure. Pertinent findings relating to pediatric and maternal health issues included data on dolutegravir-based ART in children and adolescents with HIV; safety and tolerability of dolutegravir-based ART in children and pregnant women; similarly high maternal viral suppression at 50 weeks postpartum in women receiving certain ART regimens; weight gain in pregnant women receiving dolutegravir plus tenofovir alafenamide/emtricitabine; and viral suppression with dolutegravir-based ART when started during the third trimester of pregnancy.
MeSH term(s)	Adolescent ; Adult ; Anti-HIV Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Biomedical Research ; COVID-19/drug therapy ; Congresses as Topic ; Female ; HIV Infections/drug therapy ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Male ; Oxazines/therapeutic use ; Piperazines/therapeutic use ; Pregnancy ; Pyridones/therapeutic use ; SARS-CoV-2
Chemical Substances	Anti-HIV Agents ; Antibodies, Monoclonal ; Heterocyclic Compounds, 3-Ring ; Oxazines ; Piperazines ; Pyridones ; dolutegravir (DKO1W9H7M1)
Language	English
Publishing date	2021-08-09
Publishing country	United States
Document type	Journal Article ; Observational Study
ZDB-ID	2656632-1
ISSN	2161-5853 ; 2161-5853
ISSN (online)	2161-5853
ISSN	2161-5853
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Development and Pilot of an Mpox Severity Scoring System.

Zucker, Jason / McLean, Jacob / Huang, Simian / DeLaurentis, Clare / Gunaratne, Shauna / Stoeckle, Kate / Glesby, Marshall J / Wilkin, Timothy J / Fischer, William / Damon, Inger / Brooks, John T

The Journal of infectious diseases

2023 Volume 229, Issue Supplement_2, Page(s) S229–S233

Abstract: Clinical severity scores facilitate comparisons to understand risk factors for severe illness. For the 2022 multinational monkeypox clade IIb virus outbreak, we developed a 7-item Mpox Severity Scoring System (MPOX-SSS) with initial variables refined by ... ...

Abstract	Clinical severity scores facilitate comparisons to understand risk factors for severe illness. For the 2022 multinational monkeypox clade IIb virus outbreak, we developed a 7-item Mpox Severity Scoring System (MPOX-SSS) with initial variables refined by data availability and parameter correlation. Application of MPOX-SSS to the first 200 patients diagnosed with mpox revealed higher scores in those treated with tecovirimat, presenting >3 days after symptom onset, and with CD4 counts <200 cells/mm3. For individuals evaluated repeatedly, serial scores were concordant with clinical observations. The pilot MPOX-SSS demonstrated good discrimination, distinguished change over time, and identified higher scores in expected groups.
MeSH term(s)	Humans ; Mpox (monkeypox) ; Benzamides ; Disease Outbreaks ; Isoindoles ; Monkeypox virus
Chemical Substances	Benzamides ; Isoindoles
Language	English
Publishing date	2023-11-13
Publishing country	United States
Document type	Journal Article
ZDB-ID	3019-3
ISSN	1537-6613 ; 0022-1899
ISSN (online)	1537-6613
ISSN	0022-1899
DOI	10.1093/infdis/jiad492
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.50: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 445: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito